Oramed Pharmaceuticals Inc. (ORMP) Tops Q3 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St rises as oil falls heading into US midterm elections
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts ORMP Hot Sheet
Join SI Premium – FREE
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) reported Q3 EPS of $0.15, $0.19 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.18 million.
For earnings history and earnings-related data on Oramed Pharmaceuticals Inc. (ORMP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Estee Lauder (EL) PT Raised to $129 at Goldman Sachs
- Scorpio Tankers (STNG) PT Raised to $105 at Evercore ISI
- Oppenheimer: 'We see at compelling entry point in LXEO stock at current levels'
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
